Kardigan
Kardigan is a clinical-stage cardiovascular biotechnology company developing three late-stage drug candidates (danicamtiv, ataciguat, tonlamarsen) targeting genetic dilated cardiomyopathy, calcific aortic valve stenosis, and acute severe hypertension, supported by an AI-enabled Cardiac Intelligence platform.
- Company typePublic
- Founded2023
- HeadquartersSouth San Francisco, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Kardigan does
Kardigan is a clinical-stage cardiovascular biotechnology company developing three late-stage drug candidates targeting genetic dilated cardiomyopathy (danicamtiv, Phase 2b/3), calcific aortic valve stenosis (ataciguat, Phase 2b), and acute severe hypertension (tonlamarsen, Phase 2b). All three candidates target root causes of cardiovascular disease in indications with no approved therapies, and are in-licensed from MyoKardia/BMS, Sanofi/Mayo Clinic, and Ionis respectively. The company is supported by a proprietary Cardiac Intelligence platform that integrates Prolaio's clinical intelligence technology — acquired in March 2025 — combining FDA-regulated wearable devices, 510(k)-cleared algorithms, and AI-enabled data analytics for patient identification, continuous physiologic monitoring, and optimized clinical trial design.
The company was founded in 2023 by former MyoKardia executives (MyoKardia was acquired by Bristol Myers Squibb for $13.1 billion in 2020), led by CEO Tassos Gianakakos, and is headquartered in South San Francisco with an East Coast office in Princeton. Total capital raised reached approximately $1 billion across a $300 million Series A (January 2025), a $254 million Series B (October 2025), and a $460 million IPO on Nasdaq (June 2026, ticker KARD). IPO proceeds are allocated to fund Phase 3 trials — $80–90 million each for danicamtiv and ataciguat, and $40–50 million for tonlamarsen — with operations funded through 2028.
Kardigan is pre-revenue with no approved products and operates at a loss, reporting a $56.1 million net loss in Q1 2026 and approximately $16 million in monthly cash burn. The future commercial model is planned as traditional pharmaceutical sales through specialty pharmacies and hospital channels targeting cardiologists and cardiovascular specialists upon regulatory approval, with potential functional cures across its three target indications representing a substantial addressable market.
Kardigan firmographics
Firmographics- Name
- Kardigan
- Legal name
- Kardigan, Inc.
- Website
- https://kardigan.bio
- Company type
- Public
- Founded year
- 2023
- Operating status
- Ipo
- Headcount range
- 101–250 employees
- Short description
- Kardigan is a clinical-stage cardiovascular biotechnology company developing three late-stage drug candidates (danicamtiv, ataciguat, tonlamarsen) targeting genetic dilated cardiomyopathy, calcific aortic valve stenosis, and acute severe hypertension, supported by an AI-enabled Cardiac Intelligence platform.
- Ownership category
- akta.pro rank
Kardigan industry classification
Industry- Product category
- Cardiovascular Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
- akta.pro secondary industries
- Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH), Preventive Cardiology & Lipidology (HLAKABAF)
Keywords
Where Kardigan is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Kardigan business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Pre-revenue clinical-stage biotech company. Upon regulatory approval, the company plans to commercialize its cardiovascular drug candidates through traditional pharmaceutical sales channels, generating revenue from product sales.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Kardigan product offering
Product offeringCore offering
Kardigan is a clinical-stage precision therapeutics company developing three late-stage investigational drug candidates for cardiovascular diseases: danicamtiv for genetic dilated cardiomyopathy (Phase 2b/3), ataciguat for calcific aortic valve stenosis (Phase 2b), and tonlamarsen for acute severe hypertension (Phase 2b). All three programs are in-licensed from MyoKardia/BMS, Sanofi/Mayo Clinic, and Ionis Pharmaceuticals respectively, and target root causes of cardiovascular disease in indications with no approved therapies. Drug development is supported by the proprietary Cardiac Intelligence platform integrating the acquired Prolaio clinical intelligence system with AI-enabled analytics and continuous patient monitoring via FDA-regulated wearable devices.
Product overview
Kardigan is a clinical-stage precision therapeutics company developing multiple targeted cardiovascular treatments. The company's portfolio consists of three late-stage clinical programs: Danicamtiv (direct myosin activator for genetic dilated cardiomyopathy), Ataciguat (soluble guanylyl cyclase activator for calcific aortic valve stenosis), and Tonlamarsen (antisense oligonucleotide targeting angiotensinogen for acute severe hypertension). These programs are supported by the proprietary Cardiac Intelligence platform, which integrates the acquired Prolaio clinical intelligence platform for AI-enabled data analytics, continuous physiologic monitoring via FDA-regulated devices, and optimized clinical trial design to advance precision cardiovascular medicine.
Differentiator
Problem solved
Functional benefit
Brands
- Prolaio: Clinical intelligence platform with integrated medical insights and data analytics for cardiovascular clinical development, including FDA-regulated devices and 510(k)-cleared algorithms.
- KINSHIP-DCM
- KATALYST-AV
- KARDINAL-ASH
Products and services
- Danicamtiv An investigational direct and selective activator of atrial and ventricular myosin designed to address root causes of genetic dilated cardiomyopathy (DCM) driven by myosin dysfunction in patients with inherited sarcomere variants. Currently advancing through the Phase 2b/3 KINSHIP-DCM clinical trial.
- Ataciguat An investigational soluble guanylyl cyclase (sGC) activator targeting cells and pathways underlying valvular calcification in calcific aortic valve stenosis (CAVS). Currently advancing through the Phase 2b KATALYST-AV clinical trial.
- Tonlamarsen An investigational antisense oligonucleotide targeting hepatic angiotensinogen for management of blood pressure in patients with acute severe hypertension. Currently advancing through the Phase 2b KARDINAL-ASH clinical trial.
Quantifiable outcome
- Danicamtiv demonstrated statistically significant improvements in left atrial function index and left ventricular ejection fraction in Phase 2 study for genetic DCM
- +2 more outcomes
Companies that use Kardigan
Customer profileSegments3 records
Ideal customer profiles2 records
Kardigan technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature2 records
Kardigan partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- ProlaiocoreKardigan acquired Prolaio, a cardiovascular clinical intelligence company, to enhance its heart health platform and accelerate drug development. The acquisition grants Kardigan access to Prolaio's extensive CV data set and advanced analytics.
- Bristol Myers Squibb / MyoKardiacoreKardigan in-licensed exclusive worldwide development and commercialization rights to danicamtiv from MyoKardia, which was acquired by Bristol Myers Squibb for $13.1 billion in 2020. The drug was discovered at MyoKardia and further developed by BMS before rights were licensed to Kardigan.
- Sanofi and Mayo CliniccoreKardigan acquired rights to ataciguat, an investigational soluble guanylyl cyclase activator developed by Sanofi and Mayo Clinic for the treatment of calcific aortic valve stenosis.
- Ionis PharmaceuticalscoreKardigan in-licensed exclusive worldwide development and commercialization rights to tonlamarsen, an antisense oligonucleotide discovered and developed by Ionis Pharmaceuticals for the treatment of acute severe hypertension.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
Kardigan competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Kardigan social profiles
Digital presenceKardigan financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kardigan leadership team
Management profileNumber of profiles
Profiles17 records
Kardigan subsidiaries and ownership
Company hierarchySubsidiaries1 record
Kardigan funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kardigan M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kardigan
What does Kardigan do?
Kardigan is a clinical-stage precision therapeutics company developing three late-stage investigational drug candidates for cardiovascular diseases: danicamtiv for genetic dilated cardiomyopathy (Phase 2b/3), ataciguat for calcific aortic valve stenosis (Phase 2b), and tonlamarsen for acute severe hypertension (Phase 2b). All three programs are in-licensed from MyoKardia/BMS, Sanofi/Mayo Clinic, and Ionis Pharmaceuticals respectively, and target root causes of cardiovascular disease in indications with no approved therapies. Drug development is supported by the proprietary Cardiac Intelligence platform integrating the acquired Prolaio clinical intelligence system with AI-enabled analytics and continuous patient monitoring via FDA-regulated wearable devices.
Is Kardigan a public or private company?
Kardigan is a public company. It is classified as public and is currently ipo.
When was Kardigan founded?
Kardigan was founded in 2023. It employs 101 to 250 people.
Where is Kardigan based?
Kardigan is headquartered in South San Francisco, United States, in the North America region.
How does Kardigan make money?
One revenue line is on record: pharmaceutical Product Sales.
Does Kardigan have an API?
No public API is recorded for Kardigan.
What industry is Kardigan in?
Kardigan's product category is Cardiovascular Therapeutics. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.